Bio-Rad Laboratories, Inc. (NYSE: BIO)
Health Care · Life Sciences Tools & Services · US
$361.49
-1.28% today · +21.8% 1Y
Bio-Rad Laboratories, Inc. (NYSE: BIO) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $9.78B and employs 7,450 people.
Over the last twelve months the share price has gained 21.8%, trading between 236.73 and 396.23.
Tweenvest scores Bio-Rad Laboratories, Inc. across four factors: quality 78/100, value 35/100, growth 28/100. Its strongest factor is quality.
BIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.78B
- Revenue (TTM)
- $2.59B
- P/E
- 44.35
- EPS
- 8.26
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $396.23
- 52-week low
- $236.73
- Avg volume (3M)
- —
- Shares outstanding
- 26.74M
- Employees
- 7,450
- Next earnings
- —
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- ISIN
- US0905722072
- Founded
- 1952
- Listed since
- Feb 27, 1980
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharmaron Beijing Co., Ltd.SZSE: 300759 | $10.90B | CN¥43.11 | -4.14% |
| Avantor, Inc.NYSE: AVTR | $10.60B | $15.51 | -1.02% |
| 10x Genomics, Inc.NasdaqGS: TXG | $10.51B | $74.39 | -7.76% |
| Repligen CorporationNasdaqGS: RGEN | $9.81B | $171.26 | -1.51% |
| Qiagen N.V.NYSE: QGEN | $9.38B | $45.23 | -0.33% |
| Bruker CorporationNasdaqGS: BRKR | $8.96B | $56.97 | -3.18% |
| Bachem Holding AGSWX: BANB | $7.22B | CHF80.90 | +1.06% |
| Hangzhou Tigermed Consulting Co., LtdSZSE: 300347 | $6.56B | CN¥55.18 | -5.51% |
Figures last refreshed Oct 11, 2026.